KSQ Therapeutics
6 known investors
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical Devices
Investors · 6
In the news
- Pipeline - KSQ Therapeuticsksqtx.com · 2024
- About - KSQ Therapeuticsksqtx.com · 2024
- KSQ Therapeutics raises $80m financing to advance oncology drug candidates - Pharmaceutical Business reviewpharmaceutical-business-review.com · 2018
- Cambridge startup KSQ raises another $80m, plans to start trials of cancer drugs - The Boston Globebostonglobe.com · 2018
- KSQ Therapeutics Secures $80M Financing Round - FinSMEsfinsmes.com · 2018
- KSQ raises $76M, names ex-Genzyme boss Meeker as CEO | Fierce Biotechfiercebiotech.com · 2017